Congressman Calls on DEA to Emergency-Schedule 7-OH as Opioid Threat Grows

Why it matters

A sitting U.S. congressman has formally urged the DEA to invoke its emergency scheduling authority against 7-hydroxymitragynine (7-OH), putting federal pressure on an agency that has yet to act on the FDA's own 2025 recommendation to make 7-OH a Schedule I controlled substance.

The big picture

The FDA formally asked the DEA to schedule 7-OH in the summer of 2025, but the DEA has not yet moved. Rep. Rob Bresnahan's letter to the DEA in March 2026—invoking emergency scheduling authority—adds congressional urgency to the issue. The move reflects broader concern in Congress about high-potency synthetic and semi-synthetic kratom derivatives that are widely sold in gas stations, vape shops, and online without meaningful federal oversight. A related bill in Congress, the END 7-OH Act (H.R. 8000), would amend the Controlled Substances Act to place 7-OH on Schedule I.

Key findings

• Rep. Bresnahan sent the DEA a formal letter on March 27, 2026, urging emergency scheduling of 7-OH under existing DEA authority
• The request targets chemically manipulated 7-OH products—sublingual tablets and gummies—that create rapid euphoria and heightened addiction risk
• The FDA had already recommended 7-OH's Schedule I classification in summer 2025, but DEA has not yet acted
• The END 7-OH Act (H.R. 8000) is a companion legislative effort that would directly amend the Controlled Substances Act to schedule 7-OH
• The DEA's most recent National Drug Threat Assessment does not mention kratom or 7-OH, suggesting the agency has not yet prioritized the issue

What they say

Rep. Bresnahan emphasized in his letter that "the DEA's emergency scheduling authority would effectively halt the distribution of these synthetic products while further evaluations are conducted," citing concerns raised by prior FDA recommendations about their public health implications.

Bottom line

**Congressional pressure is mounting on the DEA to emergency-schedule 7-OH kratom derivatives—more than a year after the FDA first recommended the move—as high-potency products proliferate in unregulated markets.**